NuScale Power Stock Has 195% Upside, According to This Wall Street Analyst

NuScale Power shares are down ~40% since the start of 2026, but Canaccord Genuity analyst George Gianarikas remains extremely bullish, arguing the stock has ~195% upside from its current depressed price. The bull case centers on a planned 6-gigawatt small modular reactor project tied to a partnership with ENTRA1 and TVA on the U.S. eastern coast, with a CEO expectation to sign a power purchase agreement by end-2026. Separately, a Romanian SMR project received key regulator approval, though the article notes potential commercialization delays into 2033–2034 and highlights the valuation sensitivity to an aggressive 5% terminal growth rate.

Analysis

This is still a story stock, not a cash-flow stock. The market is effectively paying today for a terminal-value outcome that requires several years of flawless execution, and that makes the valuation highly sensitive to even small disappointments in commercialization timing, project sizing, or financing terms. In that setup, analyst upside targets can amplify reflexive buying, but they do not meaningfully change intrinsic risk unless they are backed by a binding offtake contract and capital stack.

The real second-order winner, if the project progresses, is the broader nuclear ecosystem: uranium fuel-cycle names, component suppliers, and reactor-services providers get earlier revenue visibility than the developer itself. The developer remains the most exposed node because it carries the highest duration, the most financing leverage, and the greatest dilution risk if orders slip. If the project becomes real, expect money to rotate toward higher-quality nuclear enablers while SMR stays the highest-beta instrument in the group.

Near term, the stock can squeeze on headline flow, but the 1-3 month catalyst path is thin unless there is a binding PPA or project-finance milestone. The contrarian miss is that regulatory progress is not monetization; approval without firm economics can actually lengthen the runway to dilution. The thesis breaks if SMR secures a credible contracted project with bankable financing and no equity overhang; absent that, any rally looks fragile over 6-18 months.

Key Decisions for Investors

• Fade strength in SMR on analyst-driven rallies; use a 3-6 month put spread or outright short if borrow is acceptable, with a stop if a binding PPA/project-financing announcement lands.
• Pair trade: long URA or CCJ vs. short SMR for 3-6 months to express constructive nuclear sentiment while isolating single-name execution and dilution risk.
• Do not chase the move until commercial proof appears; require evidence of contracted offtake and financing before underwriting any long thesis.
• If a binding TVA/ENTRA1 PPA or similar financing milestone is announced, cover shorts immediately and reassess via 2027 call spreads rather than common stock.